奎尔素作为一种苦味受体激动剂,在头癌细胞中具有抗癌作用
Gavin Turner1, Sarah M Sywanycz1, Brianna L Buchler1
1Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania Health System, Philadelphia, PA 19104, USA.
Nutrients
|October 29, 2025
概括
苦味化合物奎尔激活了头支状细胞癌 (HNSCC) 细胞中的苦味受体 (T2Rs),降低了活力,导致线粒体去极化. 需要进一步的研究来确认T2R14调解.
科学领域:
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 奎尔在头部和部状细胞癌 (HNSCC) 中表现出临床前的抗癌作用.
- 苦味受体 (T2Rs) 在HNSCC细胞中表达,它们的激活会诱导亡.
- 增加T2R表达与改善HNSCC患者存活率相关.
研究的目的:
- 为了研究奎尔素作为HNSCC细胞中的抗癌T2R激动剂的作用.
- 评估素对 (Ca2+) 信号传递和HNSCC中的细胞活力的影响.
- 评估奎尔丁对HNSCC中线粒体去极化的影响.
主要方法:
- 通过使用T2R14对抗剂LF1和G蛋白抑制剂YM-254980 (YM) 进行活细胞成像来评估瑞丁介导的Ca2+反应.
- 在HNSCC细胞系和患者衍生瘤切片中使用水晶紫色和MTS试验评估细胞活力.
- 使用TMRE在T2R途径抑制剂的存在和缺席下测量线粒体去极化.
主要成果:
- 奎尔赛丁诱导了HNSCC细胞中的Ca2+反应,由LF1和YM显著减少.
- 奎尔赛丁在体外降低了HNSCC细胞活力;ex vivo活力下降并不显著.
- 奎尔赛丁引起了线粒体去极化,这被LF1减少了,但不是YM.
结论:
- 奎尔在HNSCC细胞中引起Ca2+反应,可能由T2R14介导.
- 奎尔丁在体外降低了HNSCC细胞活力,并诱导线粒体去极化.
- 需要使用基因淘汰/淘汰模型进行进一步的研究,以确认T2R14的参与.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
564
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
564
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
594
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
594
The Physiology of Taste
7.1K
The perception of a salty flavor is facilitated by sodium ions within the oral salivary fluid. Upon consumption of a salty substance, salt crystals disassemble, leading to the liberation of its constituents—Na+ and Cl- ions. These ions subsequently dissolve into the salivary fluid present in the oral cavity. The external environment of the gustatory cells experiences an elevation in Na+ concentration, thereby establishing a potent concentration gradient. This gradient propels the...
7.1K
Cancer Prevention
7.6K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
7.6K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K


